RESUMEN
Delayed hemolytic transfusion reaction (DHTR) is one of the most feared complications of sickle-cell disease (SCD). We retrospectively analyzed the clinical and biological features, treatments and outcomes of 99 DHTRs occurring in 69 referral center patients over 12 years. The first clinical signs appeared a median of 9.4 [IQR, 3-22] days after the triggering transfusion (TT). The most frequent DHTR-related clinical manifestation was dark urine/hemoglobinuria (94%). Most patients (89%) had a painful vaso-occlusive crisis and 50% developed a secondary acute chest syndrome (ACS). The median [IQR] hemoglobin-concentration nadir was 5.5 [4.5-6.3] g/dL and LDH peak was 1335 [798-2086] IU/L. Overall mortality was 6%. None of the patients had been receiving chronic transfusions. Among these DHTRs, 61% were developed in previously immunized patients, 28% in patients with prior DHTR. Among Abs detected after the TT in 62% of the episodes, half are classically considered potentially harmful. No association could be established between clinical severity and immunohematological profile and/or the type and specificity of Abs detected after the TT. Management consisted of supportive care alone (53%) or with adjunctive measures (47%), including recombinant erythropoietin and sometimes rituximab and/or immunosuppressants. Additional transfusions were either ineffective or worsened hemolysis. In some cases, severe intravascular hemolysis can be likely responsible for the vascular reaction and high rates of ACS, pulmonary hypertension and (multi)organ failure. In conclusion, clinicians and patients must recognize early DHTR signs to avoid additional transfusions. For patients with a history of RBC immunization or DHTR, transfusion indications should be restricted. Am. J. Hematol. 91:989-994, 2016. © 2016 Wiley Periodicals, Inc.
Asunto(s)
Anemia de Células Falciformes/complicaciones , Hemólisis , Reacción a la Transfusión/diagnóstico , Síndrome Torácico Agudo , Adulto , Arteriopatías Oclusivas , Transfusión Sanguínea , Contraindicaciones , Manejo de la Enfermedad , Femenino , Hemoglobinuria , Humanos , Isoanticuerpos/sangre , Masculino , Derivación y Consulta , Estudios Retrospectivos , Factores de Tiempo , Reacción a la Transfusión/terapia , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: The prevalence and characteristics of pulmonary hypertension in adults with sickle cell disease have not been clearly established. METHODS: In this prospective study, we evaluated 398 outpatients with sickle cell disease (mean age, 34 years) at referral centers in France. All patients underwent Doppler echocardiography, with measurement of tricuspid-valve regurgitant jet velocity. Right heart catheterization was performed in 96 patients in whom pulmonary hypertension was suspected on the basis of a tricuspid regurgitant jet velocity of at least 2.5 m per second. Pulmonary hypertension was defined as a mean pulmonary arterial pressure of at least 25 mm Hg. RESULTS: The prevalence of a tricuspid regurgitant jet velocity of at least 2.5 m per second was 27%. In contrast, the prevalence of pulmonary hypertension as confirmed on catheterization was 6%. The positive predictive value of echocardiography for the detection of pulmonary hypertension was 25%. Among the 24 patients with confirmed pulmonary hypertension, the pulmonary-capillary wedge pressure was 15 mm Hg or less (indicating precapillary pulmonary hypertension) in 11 patients. Patients with confirmed pulmonary hypertension were older and had poorer functional capacity and higher levels of N-terminal pro-brain natriuretic peptide than other patients. In contrast, patients who had a tricuspid regurgitant jet velocity of at least 2.5 m per second without pulmonary hypertension and patients with a tricuspid regurgitant jet velocity of less than 2.5 m per second had similar clinical characteristics. CONCLUSIONS: In this study of adults with sickle cell disease, the prevalence of pulmonary hypertension as confirmed on right heart catheterization was 6%. Echocardiographic evaluation alone had a low positive predictive value for pulmonary hypertension. (Funded by the French Ministry of Health and Assistance Publique-Hôpitaux de Paris; ClinicalTrials.gov number, NCT00434902.).
Asunto(s)
Anemia de Células Falciformes/complicaciones , Hemodinámica , Hipertensión Pulmonar/etiología , Adulto , Cateterismo Cardíaco/efectos adversos , Ecocardiografía Doppler , Femenino , Humanos , Hipertensión Pulmonar/diagnóstico , Hipertensión Pulmonar/epidemiología , Hipertensión Pulmonar/fisiopatología , Masculino , Prevalencia , Estudios ProspectivosAsunto(s)
Anemia de Células Falciformes/tratamiento farmacológico , Hidroxiurea/efectos adversos , Espermatogénesis/efectos de los fármacos , Adulto , Anemia de Células Falciformes/complicaciones , Antidrepanocíticos/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Recuento de Espermatozoides , Factores de Tiempo , Adulto JovenRESUMEN
Strokes are one of the most severe complications of sickle-cell disease. Most studies have been restricted to children with sickle-cell disease. To better understand the characteristics and follow-up of strokes occurring from childhood to adulthood, we undertook a retrospective cohort study of 69 stroke patients among the 2,875 patients consulting at the French Adult Sickle-Cell Disease Referral Center. Between 1970 and 2008, they had experienced 104 strokes: 80 ischemic, 22 hemorrhagic, and 2 intracranial sinus thromboses. Coma and/or fatal outcomes underscored the severity of strokes in sickle-cell disease patients.Hemorrhagic strokes occurred mostly in adults and carried a higher risk of death than ischemic stroke. The mechanisms underlying sickle-cell disease associated strokes were reevaluated and etiologies were determined for first stroke and recurrences, in childhood and adulthood. Sickle-cell disease vasculopathy concerned only SS patients and remains their most frequent stroke etiology. Cardioembolism, vaso-occlusive crisis and triggering factors were other etiologies identified in adults. Recurrences occurred in 19 SS patients only after a first ischemic stroke. SC patients' strokes occurred in adulthood and were associated with cardiovascular risk factors. Our findings provide novel information about cerebrovascular pathologies throughout the lives of sickle-cell disease patients and suggest the need for different diagnostic and therapeutic management approaches in those different settings.
Asunto(s)
Anemia de Células Falciformes/complicaciones , Accidente Cerebrovascular/etiología , Adulto , Edad de Inicio , Anciano , Isquemia Encefálica/epidemiología , Isquemia Encefálica/etiología , Hemorragia Cerebral/epidemiología , Hemorragia Cerebral/etiología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Recurrencia , Derivación y Consulta , Estudios Retrospectivos , Factores de Riesgo , Accidente Cerebrovascular/clasificación , Accidente Cerebrovascular/epidemiología , Adulto JovenRESUMEN
BCL11A was the focus of recent studies on its inhibiting effect when bound onto the ß-globin cluster in the mechanism of hemoglobin switching and HbF downregulation. We examined a cohort of 10 patients displaying different HbF levels and short deletions within the γß-δ intergenic region to find a possible correlation with the BCL11A binding site located 5' to the δ-globin gene. Precise characterization of deletions was achieved using a custom DNA-array chip and breakpoint sequencing. The α-globin cluster and major SNP associated with HbF expression were genotyped. Our results show that the loss of the BCL11A binding domain located 5' to the δ-globin gene is correlated with a strong HbF difference (mean+2.7 g/dL, ratio 2.81). This result provides evidence for the use of BCL11A level down-regulation or this domain blockage for new therapies in sickle cell disease and ß-thalassemia major patients.
Asunto(s)
Proteínas Portadoras/metabolismo , Hemoglobina Fetal/genética , Proteínas Nucleares/metabolismo , Globinas delta/genética , Globinas delta/metabolismo , Adolescente , Adulto , Sitios de Unión , Niño , Preescolar , Femenino , Hemoglobina Fetal/metabolismo , Eliminación de Gen , Expresión Génica , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Fenotipo , Polimorfismo de Nucleótido Simple , Unión Proteica , Proteínas Represoras , Adulto JovenRESUMEN
Liver involvement in SCD patients is frequent but often misdiagnosed or underestimated, except in case of advanced liver diseases. Because of so far poorly recognized forms of chronic SCD-related vascular injury that can silently evolved towards end stages or facilitate ACLF, any persisting liver function tests abnormalities should be carefully investigated, following the above proposed algorithm. Work up and management must be considered multidisciplinary in relationship with a Hepatologist. Early SCD hepatopathy should prompt revision of SCD management to prevent further liver injury and decompensation, discussing transfusion exchanges and hydro urea when not yet initiated, and control for any cofactor of liver injury. The role of HSCT in early SCD hepatopathies also deserves evaluation. In advanced SCD hepatopathies, liver transplantation, which has been rarely performed so far, is the only therapeutic option associated with improved survival. It should definitely be discussed- either electively in case of decompensation in SCD cirrhosis or jaundice/recurrent cholangitis in cholestatic diseases, with excellent outcome, - or emergently in case of ALF or ACLF with more mitigate results. To improve knowledge and management of SCD liver diseases, creation of national and international registries, as well as longitudinal observational cohorts are encouraged.
Asunto(s)
Anemia de Células Falciformes , Hepatopatías , Trasplante de Hígado , Humanos , Anemia de Células Falciformes/complicaciones , Anemia de Células Falciformes/terapia , Hepatopatías/etiología , Hepatopatías/terapia , Cirrosis Hepática/complicacionesRESUMEN
Sickle cell disease is characterized by painful vaso-occlusive crises during which abnormal interactions between erythroid adhesion molecules and vessel-wall proteins are thought to play a critical role. Hydroxyurea, the only drug with proven benefit in sickle cell disease, diminishes these interactions, but its mechanism of action is not fully understood. We report that, under hydroxyurea, expression of the unique erythroid laminin receptor Lu/BCAM was increased, but red blood cell adhesion to laminin decreased. Because Lu/BCAM phosphorylation is known to activate cell adhesion to laminin, it was evaluated and found to be dramatically lower in hydroxyurea-treated patients. Analysis of the protein kinase A pathway showed decreased intracellular levels of the upstream effector cyclic adenosine monophosphate during hydroxyurea treatment. Using a cellular model expressing recombinant Lu/BCAM, we showed that hydroxyurea led to decreased intracellular cyclic adenosine monophosphate levels and diminished Lu/BCAM phosphorylation and cell adhesion. We provide evidence that hydroxyurea could reduce abnormal sickle red blood cell adhesion to the vascular wall by regulating the activation state of adhesion molecules independently of their expression level.
Asunto(s)
Anemia de Células Falciformes/sangre , Moléculas de Adhesión Celular/metabolismo , Adhesión Celular/efectos de los fármacos , Eritrocitos Anormales/patología , Hidroxiurea/farmacología , Sistema del Grupo Sanguíneo Lutheran/metabolismo , AMP Cíclico/análisis , Humanos , Células K562 , Laminina/metabolismo , Fosforilación/efectos de los fármacosRESUMEN
Sickle cell disease (SCD) frequently affects the liver; if acute liver failure (ALF) develops, the only potentially effective therapeutic option is liver transplantation (LT). Only 12 patients for whom LT was performed for SCD-related ALF have been described so far. We report a retrospective series of 6 adult patients with SCD (3 men and 3 women, median age = 40.1 years) who underwent emergency LT. The indication for LT was ALF complicating cirrhosis in 5 patients (hepatitis C/iron overload-induced cirrhosis in 3 and iron overload-induced cirrhosis in 2); one patient had autoimmune hepatitis. The median follow-up was 52.7 months (0.5-123 months). The 1-, 3-, 5-, and 10-year survival rates were 83.3%, 66.7%, 44.4%, and 44.4%, respectively. One patient died of hepatocellular failure precipitated by hyperacute allograft rejection on post-LT day 10. Soon after LT, 2 patients developed seizures; in 1 case, the seizures were a complication of early calcineurin inhibitor-induced leukoencephalopathy. Four long-term survivors benefited from specific management of SCD; specifically, the hemoglobin S fraction was maintained below 30% and the total hemoglobin level was maintained between 8 and 10 g/dL. Two patients had mild vaso-occlusive crises. Three patients experienced a recurrence of hepatitis C virus (HCV) infection; 2 of these patients experienced reversible neurological complications while they were receiving antiviral treatment. Carefully selected patients with SCD may benefit from emergency LT. However, such patients seem to be particularly susceptible to neurological complications after LT. In contrast, severe SCD-related crises do not seem to recur if specific management is provided. Outcomes may be improved if the neurological complications can be minimized; for example, the administration of a calcineurin inhibitor can be delayed, and the management of HCV infection recurrence can be improved.
Asunto(s)
Anemia de Células Falciformes/complicaciones , Fallo Hepático Agudo/cirugía , Trasplante de Hígado , Adulto , Femenino , Humanos , Hígado/patología , Fallo Hepático Agudo/complicaciones , Masculino , Persona de Mediana EdadRESUMEN
Vaso-occlusive crisis (VOC) is the primary cause of hospitalization of patients with sickle-cell disease. Treatment mainly consists of intravenous morphine, which has many dose-related side effects. Nonsteroidal antiinflammatory drugs have been proposed to provide pain relief and decrease the need for opioids. Nevertheless, only a few underpowered trials of nonsteroidal antiinflammatory drugs for sickle-cell VOC have been conducted, and conflicting results were reported. We conducted a phase 3, double-blind, randomized, placebo-controlled trial with ketoprofen (300 mg/day for 5 days), a nonselective cyclooxygenase inhibitor, for severe VOC in adults. A total of 66 VOC episodes were included. The primary efficacy outcome was VOC duration. The secondary end points were morphine consumption, pain relief, and treatment failure. Seven VOC episodes in each group were excluded from the analysis because of treatment failures. No significant between-group differences were observed for the primary outcome or the secondary end points. Thus, although ketoprofen was well-tolerated, it had no significant efficacy as treatment of VOC requiring hospitalization. These findings argue against its systematic use in this setting.
Asunto(s)
Anemia de Células Falciformes/tratamiento farmacológico , Inhibidores de la Ciclooxigenasa/administración & dosificación , Cetoprofeno/administración & dosificación , Enfermedades Vasculares/tratamiento farmacológico , Analgésicos Opioides/administración & dosificación , Analgésicos Opioides/efectos adversos , Analgésicos Opioides/economía , Anemia de Células Falciformes/complicaciones , Anemia de Células Falciformes/economía , Inhibidores de la Ciclooxigenasa/economía , Método Doble Ciego , Femenino , Hospitalización/economía , Humanos , Cetoprofeno/economía , Masculino , Morfina/administración & dosificación , Morfina/efectos adversos , Morfina/economía , Dolor/tratamiento farmacológico , Dolor/economía , Dolor/etiología , Enfermedades Vasculares/economía , Enfermedades Vasculares/etiología , Adulto JovenRESUMEN
Hydroxyurea-derived clinical and biological benefits and safety were retrospectively studied for 123 adult patients from 2 sickle cell disease referral centers during a total follow-up of 654 patient-years and total hydroxyurea exposure of 549 patient-years. Fifty-six adverse events occurred (incidence: 12%/patient-year), with leg ulcers being the most frequent. Adverse events could arise at any time and were usually reversible. No malignancy was observed. Clinical and biological benefits of our cohort were similar to those previously reported. Based on this relatively long retrospective study, the risk/benefit ratio for moderate hydroxyurea doses was satisfactory.
Asunto(s)
Anemia de Células Falciformes/tratamiento farmacológico , Hidroxiurea/uso terapéutico , Adolescente , Adulto , Anemia de Células Falciformes/complicaciones , Antidrepanocíticos , Niño , Evaluación de Medicamentos , Femenino , Estudios de Seguimiento , Humanos , Hidroxiurea/efectos adversos , Úlcera de la Pierna/inducido químicamente , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Medición de Riesgo , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: Abnormal interactions between red blood cells, leukocytes and endothelial cells play a critical role in the occurrence of the painful vaso-occlusive crises associated with sickle cell disease. We investigated the interaction between circulating leukocytes and red blood cells which could lead to aggregate formation, enhancing the incidence of vaso-occlusive crises. DESIGN AND METHODS: Blood samples from patients with sickle cell disease (n=25) and healthy subjects (n=5) were analyzed by imaging and classical flow cytometry after density gradient separation. The identity of the cells in the peripheral blood mononuclear cell layer was determined using antibodies directed specifically against white (anti-CD45) or red (anti-glycophorin A) blood cells. RESULTS: Aggregates between red blood cells and peripheral blood mononuclear cells were visualized in whole blood from patients with sickle cell disease. The aggregation rate was 10-fold higher in these patients than in control subjects. Both mature red blood cells and reticulocytes were involved in these aggregates through their interaction with mononuclear cells, mainly with monocytes. The size of the aggregates was variable, with one mononuclear cell binding to one, two or several red blood cells. Erythroid Lu/basal cell adhesion molecule and α(4)ß(1) integrin were involved in aggregate formation. The aggregation rate was lower in patients treated with hydroxycarbamide than in untreated patients. CONCLUSIONS: Our study gives visual evidence of the existence of circulating red blood cell-peripheral blood mononuclear cell aggregates in patients with sickle cell disease and shows that these aggregates are decreased during hydroxycarbamide treatment. Our results strongly suggest that erythroid Lu/basal cell adhesion molecule proteins are implicated in these aggregates through their interaction with α(4)ß(1) integrin on peripheral blood mononuclear cells.
Asunto(s)
Anemia de Células Falciformes/metabolismo , Moléculas de Adhesión Celular/metabolismo , Eritrocitos/metabolismo , Integrina alfa4beta1/metabolismo , Sistema del Grupo Sanguíneo Lutheran/metabolismo , Monocitos/metabolismo , Adulto , Anemia de Células Falciformes/tratamiento farmacológico , Anemia de Células Falciformes/genética , Anemia de Células Falciformes/patología , Antidrepanocíticos/administración & dosificación , Agregación Celular/efectos de los fármacos , Células Cultivadas , Técnicas de Cocultivo , Eritrocitos/patología , Femenino , Humanos , Hidroxiurea/administración & dosificación , Masculino , Monocitos/patologíaRESUMEN
BACKGROUND: beta-thalassemia is a rare disease in France, encountered mainly in patients originating from Italy and North Africa. In the setting of the recent French plan for rare diseases, a National Registry for thalassemia has been developed since 2005. Epidemiological and clinical data have been collected on living patients with beta-thalassemia major or intermedia, including those who underwent hematopoietic stem cell transplantation. DESIGN AND METHODS: A standardized questionnaire was sent to clinicians throughout the national professional networks involved in the management of thalassemic patients and data were updated every 18 months. A cross-sectional study was performed in February 2009. RESULTS: Data on 378 patients (267 with thalassemia major) with a median age of 20 were recorded. Hematopoietic stem cell transplantation was performed in 52 patients. Stature, rates of parenthood, splenectomy, and cholecystectomy were no different between non-transplanted thalassemia major and thalassemia intermedia patients, after adjustment for age. Among the 215 non-transplanted thalassemia major patients, the median serum ferritin level was 1240 ng/mL and the rates of iron-related complications were 10%, 6%, 10% and 48% for cardiac failure, diabetes, hypothyroidism, and hypogonadism, respectively. From 2005 to 2008, a dramatic switch in chelation treatment, from deferoxamine to deferasirox, was observed. CONCLUSIONS: The rates of complications of iron overload in French thalassemia major patients appeared similar to those reported in other developed countries in which this condition is not endemic. There were no significant differences in height and parenthood rates between patients with the major and the intermedia forms of the disease, underlining the progress in clinical care. Future developments will focus on mortality and morbidity under oral chelation treatment.
Asunto(s)
Sistema de Registros , Talasemia beta/complicaciones , Talasemia beta/terapia , Adolescente , Adulto , Enfermedades Cardiovasculares/complicaciones , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/terapia , Niño , Preescolar , Estudios de Cohortes , Estudios Transversales , Complicaciones de la Diabetes/complicaciones , Complicaciones de la Diabetes/epidemiología , Complicaciones de la Diabetes/terapia , Femenino , Estudios de Seguimiento , Francia/epidemiología , Humanos , Lactante , Sobrecarga de Hierro/complicaciones , Sobrecarga de Hierro/epidemiología , Sobrecarga de Hierro/terapia , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Adulto Joven , Talasemia beta/epidemiologíaRESUMEN
BACKGROUND: Delayed hemolytic transfusion reaction (DHTR) is a life-threatening complication in sickle cell disease (SCD) characterized by recurrence of disease complications, recipient red blood cell (RBC) destruction, and frequently no detectable antibody. Phosphatidylserine (PS) exposure signs suicidal RBC death or eryptosis and is involved in vasoocclusive crisis (VOC). STUDY DESIGN AND METHODS: Transfusion was monitored in 48 SCD patients for up to 20 days. PS exposure was evaluated in vivo on patient RBCs (PS-RBCs) at five time points and in vitro after incubation of donor RBCs with pretransfusion plasma. RESULTS: Three VOC patients displayed DHTR with recurrent SCD features and no detectable antibody in two cases. In vitro, PS-RBC percentage was significantly increased by incubating donor RBCs with pretransfusion plasma samples from DHTR patients with no detectable antibody. No such increase was observed with samples from other patients. This result indicates that donor RBCs may be damaged by the environment of SCD patients, increasing the physiologic clearance of apoptotic RBCs. In vivo, PS-RBC percentage increased in all three cases after destruction of transfused RBCs, indicating that DHTR induces PS-RBCs and, possibly, subsequent VOC and autologous RBC destruction. CONCLUSION: This study clearly demonstrates that DHTR can occur in the absence of detectable antibody. In these cases, a mechanism of excessive eryptosis is proposed.
Asunto(s)
Anemia de Células Falciformes/terapia , Eritrocitos/citología , Hemólisis/inmunología , Reacción a la Transfusión , Adulto , Anemia de Células Falciformes/sangre , Anemia de Células Falciformes/inmunología , Muerte Celular , Eritrocitos/inmunología , Femenino , Citometría de Flujo , Humanos , Masculino , Fosfatidilserinas/metabolismo , Síndrome , Adulto JovenRESUMEN
BACKGROUND: Recent progress in the treatment of sickle cell disease, in particular the use of hydroxyurea, has considerably modified the prognosis of this disease. Many more patients now reach reproductive age. The objective of this study was to assess the potential impact of hydroxyurea on the semen of patients. DESIGN AND METHODS: In this retrospective multicenter study, we evaluated the sperm parameters and fertility of 44 patients and analyzed the potential impact of hydroxyurea. RESULTS: We report data from the largest series so far of semen analyses in patients with sickle cell disease: 108 samples were analyzed, of which 76 were collected before treatment. We found that at least one sperm parameter was abnormal in 91% of the patients before treatment, in agreement with published literature. All sperm parameters seemed to be affected in semen samples collected during hydroxyurea treatment, and this impairment occurred in less than 6 months, later reaching a plateau. Furthermore, after hydroxyurea cessation, while global results in 30 patients were not statistically different before and after hydroxyurea treatment, in four individuals follow-up sperm parameters did not seem to recover quickly and the total number of spermatozoa per ejaculate fell below the normal range in about half the cases. CONCLUSIONS: The observed alterations of semen parameters due to sickle cell disease seem to be exacerbated by hydroxyurea treatment. Until prospective studies reveal reassuring findings, we suggest that a pre-treatment sperm analysis be performed and sperm cryopreservation be offered to patients before hydroxyurea treatment.
Asunto(s)
Anemia de Células Falciformes/complicaciones , Anemia de Células Falciformes/tratamiento farmacológico , Hidroxiurea/uso terapéutico , Infertilidad Masculina/complicaciones , Semen/efectos de los fármacos , Espermatozoides/efectos de los fármacos , Adolescente , Adulto , Fertilidad , Heterocigoto , Homocigoto , Humanos , Infertilidad Masculina/etiología , Masculino , Persona de Mediana Edad , Pronóstico , Estudios RetrospectivosRESUMEN
Pyruvate kinase (PK) deficiency is asymptomatic in heterozygotes, but it can lead in homozygous neonates to a severe neonatal hemolysis, sometimes life-threatening. We report five cases, with a 1- to 17-month delayed diagnosis, highlighting the need to measure PK activity in neonates and parents in case of an hemolysis at birth.
Asunto(s)
Errores Innatos del Metabolismo/diagnóstico , Piruvato Quinasa/deficiencia , Anemia/etiología , Femenino , Pruebas Genéticas/métodos , Humanos , Lactante , Recién Nacido , Masculino , Errores Innatos del Metabolismo/complicaciones , Errores Innatos del Metabolismo/genética , Errores Innatos del Metabolismo/terapia , Mutación/genética , Tamizaje Neonatal/métodos , Polimorfismo de Longitud del Fragmento de Restricción , Resultado del TratamientoRESUMEN
Although well documented in children with sickle cell disease (SCD), the incidence, cause, and outcome of bloodstream infection (BSI) are poorly defined in adults with SCD. Through a 5-year retrospective analysis of a cohort of 900 patients followed at our institution, we identified 56 episodes of BSI in 47 patients. The incidence rate of BSI was 1.2 episodes per 100 patient-years. As compared to the patients followed in the cohort, those with BSI were more likely to be younger (p = 0.001), to have Hb-S disease (p = 0.008), severe disease (p = 0.001), or additional immunosuppression (p = 0.05). BSI was hospital-acquired in 46% of cases and mainly associated with venous catheters (41%) and Staphylococcus aureus (34%). Pneumococci were rarely identified (10.7%). Despite an adequate duration of antibiotic therapy, the course of BSI was marked by a high frequency of associated bone-joint infection. Bone-joint infection was noted in 18 patients (32% of episodes) and occurred either during the initial BSI episode (13 patients) or 1-6 months after BSI resolution (5 patients). Factors associated with the occurrence of bone-joint infection were previous osteonecrosis (relative risk, 2.5; 95% confidence interval, 1.2-5.3) and S. aureus infection (relative risk, 3.8; 95% confidence interval, 1.8-8.4). In conclusion, BSI is a rare event in adults with SCD compared to children. It mainly occurs in those with a severe underlying disease and a venous catheter. These patients have a high risk of associated bone-joint infection and therefore must be closely monitored.
Asunto(s)
Anemia de Células Falciformes/complicaciones , Enfermedades Óseas/etiología , Artropatías/etiología , Sepsis/etiología , Infecciones Estafilocócicas/complicaciones , Adulto , Anemia de Células Falciformes/terapia , Antibacterianos/uso terapéutico , Enfermedades Óseas/microbiología , Cateterismo Periférico/efectos adversos , Estudios de Cohortes , Femenino , Humanos , Incidencia , Artropatías/microbiología , Masculino , Estudios Retrospectivos , Factores de Riesgo , Sepsis/complicaciones , Sepsis/microbiología , Staphylococcus aureus/patogenicidadRESUMEN
Little is known about the pharmacokinetics of hydroxyurea in patients with sickle cell disease (SCD). Our aims were to evaluate bioequivalence between standard hydroxyurea capsules and a new formulation of 1,000 mg coated breakable tablets in adults and to compare pharmacokinetic parameters in adults and children with SCD. Fifteen adults received hydroxyurea capsules and tablets in a randomized cross-over study. Eleven children received hydroxyurea tablets. The results showed bioequivalence between capsules and tablets in adults. Pharmacokinetic parameters were not significantly different between adults and children. Considerable inter-individual variability was noted.
Asunto(s)
Anemia de Células Falciformes/sangre , Hidroxiurea/sangre , Hidroxiurea/farmacocinética , Adolescente , Adulto , Anemia de Células Falciformes/tratamiento farmacológico , Cápsulas , Química Farmacéutica , Niño , Preescolar , Estudios Cruzados , Humanos , Hidroxiurea/uso terapéutico , Persona de Mediana Edad , Comprimidos RecubiertosRESUMEN
OBJECTIVE: The aim of this prospective study was to determine the cardiorespiratory factors associated with dyspnea in patients with sickle cell SS-hemoglobin disease, with a specific interest in lung vascular involvement. MEASUREMENTS: Forty-nine patients (29 women and 20 men; mean [+/- SD] age: women, 29 +/- 6 years; men, 31 +/- 11 years) underwent direct evaluations (Borg scale evaluation during a 6-min walk test) and indirect evaluations (modified Medical Research Council [MRC]score) of their dyspnea, pulmonary function tests (PFTs) [spirometry, volumes, diffusing capacity of the lung for carbon monoxide (Dlco), diffusing capacity of the alveolar-capillary membrane, and pulmonary capillary blood volume measurements], echocardiography, and biological evaluation. RESULTS: Thirty-four patients complained of significant breathlessness (MRC score, > 1). Indirect and direct evaluations of dyspnea were correlated. PFT results depicted a very mild restrictive pattern (mean total pulmonary capacity, 86 +/- 11% predicted) and an impairment of Dlco (mean Dlco corrected for the degree of anemia, 69 +/- 13% predicted). The statistical analysis demonstrated that dyspnea and exercise performance were closely linked to indexes of Dlco but not with any echocardiographic or biological measure including anemia. Nevertheless, only approximately 25% of the variability was explained by these associations. Despite having a similar history of vasoocclusive crisis events, women had more severe anemia, dyspnea, decreases in Dlco (corrected for the degree of anemia), and a higher capillary blood volume (corrected for alveolar volume) than men. CONCLUSION: Lung vascular disease contributes to dyspnea and the exercise limitation of patients with sickle cell disease. A sequential assessment of Dlco would therefore constitute one of the objective functional end points for follow-up studies of these patients.
Asunto(s)
Anemia de Células Falciformes/epidemiología , Disnea/epidemiología , Enfermedades Pulmonares/epidemiología , Adulto , Anemia de Células Falciformes/fisiopatología , Pruebas Respiratorias , Disnea/fisiopatología , Femenino , Humanos , Enfermedades Pulmonares/fisiopatología , Masculino , Óxido Nítrico/metabolismo , Estudios Prospectivos , Alveolos Pulmonares/metabolismo , Capacidad de Difusión Pulmonar , Pruebas de Función RespiratoriaRESUMEN
INTRODUCTION: An understanding of the causes of death among patients with sickle cell disease may be informative for both epidemiology and pathogenesis. This information should aid anticipation of dangerous clinical conditions, counselling patients and design of preventive therapies. PATIENTS AND METHODS: All deaths known to four European sickle cell disease centres over a 10-year period were retrospectively analysed. The circumstances of death were classified as follows: (1) acute sickle related vaso-occlusion; (2) chronic organ failure related to sickle cell disease; (3) infection; and (4) miscellaneous causes. RESULTS: Sixty-one adult patients (mean age: 32+/-11 years) died during the study period. Twelve patients suddenly died at home; most of them exhibited symptoms of vaso-occlusion but in eight patients, the cause of death was unknown. The primary cause of death in the 53 evaluable patients was sickle related vaso-occlusion (27 out of 53; 51%) which manifested mainly by acute multiorgan failure (n=13) and acute chest syndrome (n=9). Ten of the 27 patients (37%) who died in these circumstances had an apparent mild disease before their deaths. Ten patients (19%) died of documented infection. Ten of the evaluable patients (19%) died of a chronic terminal visceral involvement related to sickle cell disease which was mainly liver cirrhosis. Four patients died by suicide or because of refusal of care and two patients died of iatrogenic complication. CONCLUSION: The primary cause of death in adults appears to be vaso-occlusive, even in patients with no overt organ-system failure. Our results emphasise that the circumstances of death in sickle cell disease are different between adults and children. The deaths among adults appear not to be easily assigned to a few preventable causes as they are in children.